Stage 4 Breast Cancer: 14% of Patients Carry Hereditary Risk

In metastatic (stage 4) breast cancer patients, a case series published on 29 August 2019 in JAMA Oncologyfound "pathogenic / likely pathogenic" germline variants (genetic changes) in 14% using multigene panel testing.
Compared with older hereditary breast cancer tests assessing only BRCA1 and BRCA2, multigene tests provided approximately twice as much information about genetic diversity, as a study published in 2018 in JAMA Oncology had shown.
Why Does This Matter?
Researchers argue that current US National Comprehensive Cancer Network (NCCN) germline testing criteria are too narrow. Until recently, fewer than 10% of breast cancers were thought hereditary, but new findings suggest up to 15%.
Testing only known BRCA1 and BRCA2 mutations is insufficient for heredity in metastatic breast cancer. Identifying mutations in other associated genes such as ATM, BRIP1 and CHEK2 may indicate effectiveness of new-generation PARP inhibitors. Although FDA approval for breast cancer use beyond BRCA mutations is lacking, trials continue.
Study Design and Results
A series of 100 metastatic breast cancer patients underwent germline testing with a 30-gene panel regardless of NCCN recommendations.
- Of 100 cases, 14 (14%) had pathogenic / likely pathogenic hereditary alterations.
- Of these cases, 6 (43%) did not meet NCCN testing criteria.
- Among 14 Patients:
- 6 had a BRCA mutation.
- 1 had an ATM mutation.
- 1 had a BRIP1 mutation.
- 1 had a CHEK2 mutation.
- 21% had mutations of unknown clinical significance.
The single-center design is the main limitation. The small sample (100) may underestimate the true frequency of germline hereditary changes.
Who Should Undergo Genetic Testing for Hereditary Breast Cancer?
- If the mother, grandmother, sibling or maternal aunt had breast cancer before 50
- If on the maternal or paternal side there are both ovarian and breast cancer cases
- If the family includes someone with triple-negative breast cancer
- If, besides breast cancer, the family has prostate, skin, pancreatic, stomach, uterine, thyroid or colon cancers or sarcoma
- If any family member had cancer in both breasts
- Ashkenazi Jewish ancestry
- If the family includes a man with breast cancer among its members
- If the same person had both breast and ovarian cancer
- If a hereditary breast cancer-associated gene mutation is known in the family
Testing is recommended for individuals with any of these circumstances. A hereditary mutation in a family does not mean every family member carries it.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.